Epclusa

sofosbuvir/velpatasvir

FDA approved for HIV/HCV co-infection
Genotype
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6

Standard Dose

One tablet once daily, usually for 12 weeks, with or without food. See treatment table for this page online. Each tablet contains 400 mg of sofosbuvir and 100 mg of velpatasvir. Ribavirin may be added in patients with decompensated cirrhosis. The brand name is dispensed in a bottle, and the authorized generic is dispensed in a blister pack. The authorized generic was created to help lower cost and has identical ingredients as the brand name.

Sofosbuvir-based regimens are not recommended in people with creatinine clearance (CrCl) less than 30 mL/min.

Take missed dose as soon as possible, unless it is closer to the time of your next dose. Do not double up on your next dose.

BLACK BOX WARNING

Before starting treatment with any direct-acting antiviral (DAA), including Epclusa, patients should take a blood test to check for hepatitis B (HBV) infection. HBV infection could get worse or reactivate during or after DAA treatment, potentially leading to serious liver problems, including liver failure or death. Patients with current or past HBV infection should be monitored during HCV DAA treatment, and some may need to take HBV treatment. See HBV Reactivation page for more information and consult your medical provider.

Manufacturer

Gilead Sciences

AWP

$29,904 / month; authorized generic: $9,600 / month

Potential Side Effects and Toxicity

Potential Drug Interactions

More Information